FORM 6 - K
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16 of
The Securities Exchange Act of 1934
For the month of July 2000
Commission File Number 0-29350
VASOGEN INC.
(Translation of Registrant's name into English)
2155 Dunwin Drive, Suite 10, Mississauga, Ontario, L5L 4M1
(Address of principal executive offices)
(Indicate by check mark whether the registrant files or will file annual reports
under cover Form 20 - F or Form 40 - F.)
Form 20 - F X Form 40 - F
----- -----
(Indicate by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of
1934.)
Yes No X
----- -----
This Form 6-K consists of:
A press release issued by Vasogen Inc. on July 18, 2000, entitled: "Vasogen Adds
to Senior Management Team".
SIGNATURE
---------
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
VASOGEN INC.
By
--------------------------------
(Name: Christopher Waddick)
(Title: Vice-President, Finance & CFO)
Date: July 19, 2000
<PAGE>
Vasogen Inc. INVESTOR CONTACT
2155 Dunwin Drive Glenn Neumann
Mississauga, ON, Canada L5L 4M1 Investor Relations
tel: (905) 569-2265 fax: (905) 569-9231 tel: (905) 569-9065
http://www.vasogen.com e-mail: [email protected]
--------------------------------------------------------------------------------
FOR IMMEDIATE RELEASE
Vasogen Adds to Senior Management Team
Toronto, Ontario (July 18, 2000) -- Vasogen Inc. (TSE:VAS; AMEX:MEW) is pleased
to announce the addition of Clive Ward-Able, MD, to its senior management team
as Vice-President, Research and Development. Dr. Ward-Able will hold overall
responsibility for directing the Company's research and development program.
Dr. Ward-Able has built a successful international career in the pharmaceutical
industry. He most recently held the position of Medical and Healthcare Director
for Roche Products, U.K., a division of Roche Pharmaceuticals, where he was
responsible for a wide range of activities, including medical affairs, clinical
trials management, medical support for strategic marketing and new product
introductions. He also held senior management positions at Roche in Basel,
Switzerland, including Head of Medical Support for International Strategic
Marketing and International Medical Manager, Transplantation and has served as
Medical Marketing Director at Roche Canada. Prior to joining Roche, Dr.
Ward-Able served as Product Manager for Eli Lilly, Johannesburg, South Africa.
Dr. Ward-Able holds a Bachelor degree in Pharmacy from Rhodes University and a
Medical degree from the University of Stellenbosch, both located in South
Africa.
"Dr. Ward-Able's extensive experience in the area of product development and
marketing will be a valuable asset as we advance the commercial development of
our products," remarked David Elsley, President and CEO of Vasogen. "In
particular, this important addition to our senior management team allows Dr.
Tony Bolton, Vasogen's Director of Research, to continue his focus on the basic
research that is fundamental to the continued expansion of our product
pipeline."
Vasogen is focused on developing immune modulation therapies to advance the
treatment of cardiovascular, autoimmune and related inflammatory diseases.
These therapies are designed to target fundamental disease-causing events,
providing safe, effective treatment.
Statements contained in this press release, including those pertaining to
scientific and clinical research, commercialization plans, strategic alliances,
and intellectual property protection, other than statements of historical fact,
are forward-looking statements subject to a number of uncertainties that could
cause actual results to differ materially from statements made.
